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imely differentiation of progenitor cells is critical
for development. In this study we asked whether
global epigenetic mechanisms regulate timing of
progenitor cell differentiation into myelin-forming oligo-
dendrocytes in vivo. Histone deacetylation was essential
during a speciﬁc temporal window of development and
was dependent on the enzymatic activity of histone
deacetylases, whose expression was detected in the de-
veloping corpus callosum. During the ﬁrst 10 postnatal
days, administration of valproic acid (VPA), the speciﬁc
inhibitor for histone deacetylase activity, resulted in sig-
T
 
niﬁcant hypomyelination with delayed expression of late
differentiation markers and retained expression of pro-
genitor markers. Differentiation resumed in VPA-injected
rats if a recovery period was allowed. Administration of
VPA after myelination onset had no effect on myelin
gene expression and was consistent with changes of nu-
cleosomal histones from reversible deacetylation to more
stable methylation and chromatin compaction. Together,
these data identify global modiﬁcations of nucleosomal
histones critical for timing of oligodendrocyte differentia-
tion and myelination in the developing corpus callosum.
 
Introduction
 
The identification of mechanisms modulating timing of cellular
differentiation is critical for morphogenesis and proper develop-
ment. In this study we have addressed this issue in the oligoden-
drocyte (OL) lineage. OLs are the myelin-forming cells of the
central nervous system and they derive from progenitor cells
generated by multipotent precursors. The concept of timing of
OL differentiation was originally proposed based on very ele-
gant studies on cultured progenitors purified from the optic
nerve (Temple and Raff, 1986). Since then, other studies have
confirmed, refuted, or modified this concept (Barres et al.,
1994; Ibarrola et al., 1996) and attempts have been made to
identify the molecular “effectors” of the timing mechanism. In
studies on progenitors from the developing optic nerve, for in-
stance, it had been proposed that timing of OL differentiation
was linked to cell cycle exit and that the cell cycle inhibitor
p27Kip1 was a major component of the timing mechanism
(Durand et al., 1997, 1998; Durand and Raff, 2000). This hy-
pothesis implied that OL differentiation proceeded by default
once the cells exited from the cell cycle. However, overexpres-
sion of p27Kip1 in vitro was not sufficient to initiate OL differ-
entiation (Tikoo et al., 1998; Tang et al., 2000), and in vivo phe-
notypic analysis of the p27Kip1 null mice revealed no delay in
timing of myelination (Casaccia-Bonnefil et al., 1997, 1999).
Additional studies have suggested the role of transcriptional in-
hibitors such as the basic helix-loop-helix molecules Id2 (Wang
et al., 2001), Id4 (Kondo and Raff, 2000b), and Hes5 (Kondo
and Raff, 2000b). However, it is unlikely that any single compo-
nent could recapitulate the process of timely OL differentiation.
The premise of this study is that the progression along the
OL lineage is a complex event characterized by global changes in
gene expression, resulting in loss of precursor markers and differ-
entiation inhibitors and acquisition of late differentiation mark-
ers, including enzymes for the synthesis of myelin lipids and my-
elin proteins, such as ceramide-galactosyl-transferase (CGT),
myelin basic protein (MBP), and myelin-associated glycoprotein
(MAG). We had previously reported that global changes affect-
ing deacetylation of nucleosomal histones were critical for OL
differentiation in vitro (Marin-Husstege et al., 2002). Reversible
acetylation of selected lysine residues in the conserved tails of
nucleosomal core histone proteins represents an efficient way to
regulate gene expression (for reviews see Strahl and Allis, 2000;
Turner, 2000; Yoshida et al., 2003; Yang, 2004). In general, in-
creased histone acetylation (hyperacetylation) is associated with
increased transcriptional activity, whereas decreased acetylation
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(hypoacetylation or deacetylation) is associated with repression
of gene expression (Forsberg and Bresnick, 2001; Wade 2001).
The removal of acetyl groups from lysine residues in the
histone tails is performed by specific enzymes called histone
deacetylases (HDACs) that can be broadly grouped into three
major classes. Class I includes HDAC-1, -2, -3, and -8 and is
composed of small proteins (377–488 aa), sharing sequence ho-
mology to the yeast transcriptional regulator RPD3 (Bjerling et
al., 2002), and a broad expression pattern. Class II includes
HDAC-4, -5, -6, -7, and -9 and is composed of proteins of larger
size (669–1215 aa), sharing sequence homology with the yeast
HDA1 (Fischle et al., 2002), and a restricted expression pattern
(de Ruijter et al., 2003). Class III HDACs, the Sir2 family pro-
teins, includes molecules that are sensitive to the redox state of
the cell and are inhibited by a different category of pharmacolog-
ical inhibitors (Grozinger et al., 2001) than the other two classes
(Phiel et al., 2001; Gottlicher, 2004; Gurvich et al., 2004).
Because the acetylation state of nucleosomal histones
modulates chromatin structure and epigenetically regulates
gene expression, we hypothesized that this could be the global
mechanism responsible for timing of OL progenitor differentia-
tion in vivo. We addressed this question in the developing corpus
callosum because timing of myelination of this region has been
thoroughly characterized (Bjelke and Seiger, 1989; Hamano et
al., 1996, 1998) and because of its functional relevance as the
major myelinated fiber tract of the adult brain. The corpus callo-
sum is composed of millions of fibers that need to be properly
myelinated to allow communication between the two brain hemi-
spheres. Myelination in this structure follows a precise timing,
during the first two postnatal weeks of development (Bjelke and
Seiger, 1989; Hamano et al., 1996, 1998), and a precise topology,
starting at caudal levels and progressing rostrally (Smith, 1973)
and starting laterally and proceeding medially (Smith, 1973).
In this study we asked whether deacetylation occurred in
OL progenitors residing in the developing anterior corpus cal-
losum and whether inhibition of this process in vivo would af-
fect timing of myelination.
 
Results
 
Global changes in gene expression 
correlate with progressive histone 
deacetylation in the developing corpus 
callosum
 
OL differentiation in the rostral corpus callosum was character-
ized by the synthesis of late differentiation markers including
Figure 1. Global changes of gene expression in the developing corpus callosum correlated with decreased protein acetylation. (A) RT-PCR of total
RNA extracted from the anterior corpus callosum of p1, p5, p11, and p24 rats and amplified with primers for CGT, MAG, MBP, and Sox10 and actin.
(B) RT-PCR of total RNA amplified with primers for Notch-1, Jagged-1, nestin, tenascin, and actin. (C) Western blot of protein extracted from the anterior
corpus callosum at the indicated time points and probed with anti-acetyl-lysine (AcLys) antibodies. Actin was used as loading control. Note the deacetyla-
tion of the14-kD band (arrow) occurring at the onset of myelination. (D–I) Coronal brain sections from p5 (D–F) and p24 (G–I) were stained with AcLys
(D, F, G, and I, green), CC1 (F and I, red), and DAPI (blue) as counterstain. Bar, 20  m. 63  objective, LSM510 microscope (Carl Zeiss MicroImaging, Inc.).
Double-labeled CC1 /AcLys  cells (F and I, white arrows) were counted within the same area of the medial corpus callosum at each time point and
referred to the total number of CC1  cells. The differences between the two time points were statistically different (P   0.001) (J). These data are repre-
sentative of at least three independent experiments using three individual rat pups for each time point. 
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MBP, MAG, and CGT, the progressive increase of the transcrip-
tion factor Sox10 (Fig. 1 A), and the loss of precursor markers
including tenascin, nestin, and Notch1 (Fig. 1 B). Because OL
differentiation was associated with such generalized changes in
progenitors, we hypothesized that global changes affecting chro-
matin components could modulate timing of myelination in the
corpus callosum by modulating gene expression. Histone acety-
lation is one of the best-characterized mechanisms of regulating
gene expression, and we therefore investigated whether it oc-
curred in the developing corpus callosum. Several acetylated
proteins ranging between 10 and 100 kD were detected in West-
ern blot analysis of protein extracts from the rostral corpus callo-
sum at postnatal day 1 (p1), p5, p11, and p24 (Fig. 1 C). Of these
bands, only the 14- and the 30-kD protein displayed a distinctive
temporal pattern of deacetylation. The 30-kD band lost its acetyl
groups only during the third postnatal week (Fig. 1 C). Deacety-
lation of the 14-kD band, in contrast, started at p5 and continued
throughout the period coincident with the onset of myelination.
The acetylation level of this protein, therefore, correlated with
high expression of progenitor markers and progressively de-
creased during OL differentiation. The occurrence of protein
acetylation in OL lineage cells in the medial region of the body
of the corpus callosum was confirmed by immunohistochemistry
using the antibody recognizing the OL differentiation marker
CC1 (Fig. 1, D–I). At p5, the number of double-positive CC1
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(Fig. 1 J). The 14-kD band corresponded to acetylated histone
H3 (AcH3), as determined by Western blot analysis (Fig. 2 A),
and the presence of AcH3 in the nuclei of OL progenitors in the
developing corpus callosum was further characterized by immu-
nofluorescence for the marker Sox10 (Fig. 2, B–D) and NG2
(Fig. 2, E–G). Remarkably, in the medial region of the body of
the corpus callosum at rostral levels, the majority of the Sox10
 
 
 
cells (Fig. 2 D) and of the NG2
 
 
 
 cells (Fig. 2 G) were also
AcH3. To confirm the progressive decrease in AcH3 during OL
development, we also processed p5 and p24 brain sections for
Figure 2. Histone H3 acetylation in OL progenitors of the medial corpus callosum progressively decreased during postnatal development. The 14-kD protein
undergoing deacetylation during the first two postnatal days was identified by Western blot analysis using antibodies recognizing acetylated histone H3
(AcH3) and actin as loading control (A). To confirm that AcH3 was present in the nuclei of cells of the OL lineage, brain sections were labeled with anti-
bodies against AcH3 (B, D, E, and G, green), Sox10 (B and D, red), NG2 (E and G, red), and DAPI (blue) as nuclear counterstain. Bar, 20  m. 63 
objective, LSM510 microscope (Carl Zeiss MicroImaging, Inc.). Double-positive cells are indicated by white arrows. (H–M) Confocal images of the medial
corpus callosum at p5 and p24 stained for AcH3 (H, J, K, and M, green), CC1 (J and M, red), and DAPI (blue). Compare the similar density of DAPI 
nuclei with the decrease of CC1 /AcH3  cells (J and M, white arrows). The CC1 /AcH3  cells were counted and referred to the total number of
CC1  cells (N). The bar graph shows the statistically significant (P   0.001) decrease of AcH3 /CC1  cells from p5 to p24. 
JCB • VOLUME 169 • NUMBER 4 • 2005 580
 
CC1 and AcH3 staining (Fig. 2, H–M) and counted the number
of double-positive cells. At p5, the total number of CC1
 
 
 
/
AcH3
 
 
 
 cells was 716 
 
 
 
 29 per mm
 
2
 
 (
 
n
 
 
 
 
 
 3), whereas at p24 this
number was reduced to 234 
 
 
 
 29 per mm
 
2
 
 (
 
n
 
 
 
 
 
 3), thus resulting
in a 40% decrease in the number of double-positive cells (Fig. 2
N). Together, these data suggest that progressive deacetylation of
histone H3 occurs in cells of the OL lineage, during a critical
temporal window coincident with timing of OL differentiation
and myelin gene expression in the developing corpus callosum.
 
Decreased protein acetylation is due to 
the activity of class I HDACs
 
Because deacetylation is due to the removal of acetyl groups
from lysine residues mediated by specific enzymes called
HDACs, we tested the HDAC enzymatic activity in protein ex-
tracts from the developing corpus callosum, using a fluorimet-
ric assay (Fig. 3 A). High levels of HDAC activity were de-
tected during the first two weeks of postnatal development and
progressively decreased during the third postnatal week (Fig.
3 A). Because the acetylation level of proteins at any time point
reflects the equilibrium between the addition and the removal
of acetyl groups (Lehrmann et al., 2002), these data suggest
that at p1, despite the high levels of HDAC activity, the equi-
librium is in favor of acetylation, whereas starting from p5 it is
in favor of deacetylation. To determine the class of HDAC re-
sponsible for the effect, the experiments were repeated in the
presence of the class I and II HDAC inhibitor trichostatin A
(TSA), and of the class III HDAC inhibitor sirtinol. TSA de-
creased the total HDAC activity in the tissue extracts of devel-
oping corpus callosum of 
 
 
 
90% (Fig. 3 A), whereas sirtinol
did not block the HDAC enzymatic activity and it actually in-
duced further activation, possibly due to removal of inhibitory
acetyl groups regulating class I and II HDACs.
Given the existence of a large number of isoforms for
class I and class II HDACs, it was important to determine their
expression and functional relevance in the developing corpus
callosum. Western blot analysis of protein extracts from the
rostral corpus callosum, dissected at distinct developmental
time points, revealed the presence of all the HDACs isoforms
(Fig. 3 B). No major change in protein expression was ob-
served for HDAC-1 to HDAC-8, whereas HDAC-7 levels de-
creased around p8 (Fig. 3 B). Interestingly, HDAC-1 and
HDAC-8 both showed the presence of additional higher molec-
ular weight bands at p24, possibly resulting from post-transla-
tional modifications of these molecules. The temporal and
cellular patterns of HDAC expression in the developing cor-
pus callosum were further assessed using double immunohis-
tochemistry with CC1 and antibodies specific for each HDAC
isoform (Fig. 4). At p5, the class I isoforms HDAC-1, -2, -3,
and to a lesser degree HDAC-8 were expressed in the nucleus
of CC1
 
 
 
 cells (Fig. 4, A–C, H). The class II isoforms HDAC-4,
-5, -6, and -7, in contrast, were weakly expressed and localized
in the cytoplasm (Fig. 4, D–G). HDAC-4 was completely ab-
sent from CC1
 
 
 
 cells and its filamentous staining pattern was
suggestive of axonal staining or myelinated fibers in the devel-
oping corpus callosum (Fig. 4 D). By p24, when myelination
had ensued, the immunoreactivity for several HDAC isoforms,
including HDAC-2, -3, -5, and -8, decreased in CC1
 
 
 
 cells (Fig.
4, J, K, M, and P). In contrast, HDAC-1 was still expressed in
the nucleus of the CC1
 
 
 
 cells as well as in myelinated fibers
(Fig. 4 I), HDAC-4 displayed a strong filamentous staining
similar to p5 (Fig. 4 L), and HDAC-6 and -7 were still in the
cytosol of CC1
 
 
 
 cells (Fig. 4, N and O).
Due to the nuclear localization of class I HDACs in the
p5 corpus callosum, we confirmed the cellular specificity of
these isoforms by immunolabeling with antibodies specific for
oligodendrocytic (i.e., CC1), neuronal (i.e., NeuN), and astro-
cytic (i.e., GFAP) markers (Fig. 5). The majority of the
HDAC-1–positive cells were identified as OLs because they
were immunoreactive predominantly for CC-1 (Fig. 5 A), but
not for NeuN (Fig. 5 B) or GFAP (Fig. 5 C). In contrast, a large
Figure 3. Total HDAC activity in extracts of the developing rostral corpus
callosum. (A) Total HDAC activity was measured in protein extracts from
anterior corpus callosum at p1, p5, p8, p11, and p24 using an acety-
lated fluorimetric substrate (black bars). The experiments were then re-
peated by incubating the same samples with TSA (white bars), or with
sirtinol (hatched bars). (B) The protein levels of distinct HDAC isoforms
were assessed by Western blot analysis on the same tissue extracts. Blots
were probed with antibodies against class I (HDAC-1, -2, -3, and -8) and
class II (HDAC-4, -5, -6, and -7), and actin as loading control. 
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part of HDAC-2–positive cells were also NeuN
 
 
 
 (Fig. 5 E)
and GFAP
 
 
 
 (Fig. 5 F). A similar pattern of expression was ob-
served for HDAC-3 (Fig. 5, G–I) and HDAC-8 (Fig. 5, J–L),
which were both expressed in all three cell types.
Together, these data show that during the first week of
postnatal development, only class I HDACs are present in the
nuclei of the differentiating OL cells, thus suggesting that his-
tone deacetylation in these cells is likely due to the activity of
class I HDAC isoforms.
 
Inhibiton of HDAC activity prevents 
myelin gene expression in the developing 
corpus callosum only during a critical 
temporal window
 
To address the functional relevance of histone deacetylation on
OL differentiation and myelination, we investigated the effect
of in vivo administration of the pharmacological inhibitor of
class I HDACs, valproic acid (VPA). The short-term experi-
mental paradigm included three groups of neonatal pups receiv-
ing a 2-d regimen of VPA (300 mg/kg body weight) starting at
distinct developmental time points (Fig. 6 A). The first group
of neonatal rats (
 
n
 
 
 
 
 
 12) was injected with PBS (
 
n
 
 
 
 
 
 6) or
VPA (
 
n
 
 
 
 
 
 6) at p6 and p7 and then harvested at p8 (injection 1),
at the beginning of myelination. The second group (
 
n
 
 
 
 
 
 12)
was injected at p9 and 10 and harvested at p11 (injection 2),
whereas the third group (
 
n
 
 
 
 
 
 12) was injected at p19 and 20
and harvested at p21 (injection 3), after myelination had ensued
in the rostral corpus callosum.
The hypothesis that HDAC activity was required for
changes in gene expression associated with OL differentiation
Figure 4. Cellular and temporal profile of expression of class I and II HDACs in maturing OLs. Confocal images of the medial part of the body of the
corpus callosum at rostral levels, identified in coronal brain sections from p5 (A–H) and p24 (I–P) neonatal rats, after staining with antibodies for HDAC-1
to -8 (A–P, green) and for CC1 (A–P, red). Bar, 20  m. 63  objective, LSM510 confocal microscope (Carl Zeiss MicroImaging, Inc.).
Figure 5. Cell specificity of class I HDAC expression during the first post-
natal week of development. Immunohistochemistry of coronal brain sec-
tions from p5 rat pups stained with antibodies against HDAC-1, -2, -3,
and -8 (A–L, green), CC1 (A, D, G, and J, red), NeuN (B, E, H, and K, red),
and GFAP (C, F, I, and L, red). Bar, 20  m. 25  objective, DM RA (Leica).
Each immunostaining was performed at least three times from three dis-
tinct p5 rat brains. 
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predicted that in vivo treatment with HDAC inhibitors pre-
vented OL differentiation and possibly caused hypomyelina-
tion of axonal fibers in the developing corpus callosum. In
agreement with this hypothesis, the expression of OL differen-
tiation genes was significantly down-regulated in animals that
received VPA injection during the first two postnatal weeks
(Fig. 6 B). The effect of VPA on myelin gene expression was
dramatic if started during the first postnatal week, but it was in-
effective if started during the third postnatal week (Fig. 6 B).
Decreased myelin gene expression in the VPA-treated pups
was associated with a decreased number of mature OL and my-
elinated fibers, as assessed by MAG and MBP immunoreactiv-
ity. In PBS-injected pups at p8, myelination in the corpus callo-
sum followed the latero-medial gradient, as assessed by the
large number of MAG
 
 
 
 and MBP
 
 
 
 cells and fiber in the lat-
eral (Fig. 6, C and I) but not in the medial (Fig. 6, D and J) re-
gion. Several myelinated fibers could also be detected in the
anterior commissure (Fig. 6, E and K). In VPA-injected pups,
in contrast, the number of MAG
 
 
 
 and MBP
 
 
 
 cells and fibers
was decreased both in the lateral (Fig. 6, F and L) and medial
(Fig. 6, G and M) corpus callosum as well as in the anterior
commissure (Fig. 6, H and N).
Decreased MAG and MBP immunoreactivity in the corpus
callosum of VPA-treated pups was accompanied by a reduc-
tion in the number of CC1
 
 
 
 cells (Fig. 7, A–E). This de-
crease was not due to a toxic effect of the pharmacological
inhibitor because the total number of DAPI
 
 
 
 cells/mm
 
2
 
 was
quite stable (x 
 
 
 
1488 
 
 
 
 49 in VPA injected and x 
 
 
 
1563 
 
 
 
52 in PBS control) and because there was no difference in the
number of TUNEL
 
 
 
 (unpublished data) apoptotic cells in
the two groups. The reduced number of CC1
 
 
 
 cells was
likely due to delayed differentiation, as indicated by the in-
creased percentage of cells expressing the bipotential progen-
itor marker NG2
 
 
 
 in VPA-treated animals compared with
controls (Fig. 7, F–H). The increased progenitor number was
not due to an effect of VPA on proliferation, because the
number of proliferating NG2
 
 
 
 cells, identified by in vivo la-
beling with the thymidine analogue BrdU, was very similar
in treated and control rats (Fig. 7, I–M). The inhibitory effect
of VPA on differentiation was also supported by the detec-
tion of PSA-NCAM
 
 
 
 precursors in cells in the subcortical
white matter of treated animals (Fig. 7, N–Q). Together,
these data suggest that short-term inhibition of HDAC activ-
ity does not impair the ability of OL progenitors to exit the
cell cycle, but arrests their differentiation at a stage charac-
terized by the expression of early progenitor traits and lack of
differentiation markers.
Because a 3-d VPA treatment resulted in hypomyelina-
tion, we asked whether prolonged treatment would inhibit my-
elination even more. To test this hypothesis, pups were subject
to a 7-d injection protocol (Fig. 8 A) starting at p3 and followed
by the assessment of myelination at p10 (Fig. 8, B–M). In p10
control animals myelination was almost complete in the lateral
region of the anterior corpus callosum (Fig. 8, B and H) and in
the anterior commissure (Fig. 8, D and J), as indicated by the
presence of several CC1
 
 
 
 and MAG
 
 
 
 cells and by the intense
MAG and MBP immunoreactivity of the myelinated fibers. At
p10 OL differentiation and myelination were detected also in
Figure 6. Pharmacological blockers of HDAC
activity induced hypomyelination when admin-
istered during a critical temporal window of
development. (A) Schematic representation of
three distinct PBS/VPA injection paradigms to
the neonatal rats. Each group was composed
of 12 animals, receiving four injections (ar-
rows) of either PBS (n   6) or VPA (n   6) at
the indicated times. Harvest time is indicated
by the asterisk. (B) Semi-quantitative RT-PCR
analysis of the effect of the three treatments on
myelin gene expressions. Total RNA was iso-
lated at each time point (3 PBS- and 3 VPA-
injected  pups), and the reverse-transcribed
cDNA was amplified using primers specific to
MAG, CGT, and MBP, and actin as loading
control. (C–N) MAG  immunofluorescence in
control animals was detected in the soma of
OL and in myelinated fibers in the lateral cor-
pus callosum (C, lat. cc, green), in the soma of
OL in the medial corpus callosum (D, med. cc,
green), and in the anterior commissure (E, ac,
green). Fewer MAG  cells and myelinated fi-
bers were detected in the lateral (F) and medial
(G) corpus callosum, and in the anterior com-
missure (H) of VPA-injected rats. (I–N) The pat-
tern of MBP immunofluorescence was similar
and showed several myelinated fibers in the
lateral corpus callosum (I) and in the anterior
commissure (K) of control rats and very few
MBP  fibers in the same brain regions of VPA-
treated animals (L–N). Bar, 20  m. 63  ob-
jective,  LSM510 confocal microscope (Carl
Zeiss MicroImaging, Inc.).CHROMATIN CHANGES IN THE DEVELOPING CORPUS CALLOSUM • SHEN ET AL. 583
the medial corpus callosum (Fig. 8, C and I) of PBS-injected
pups. The effect of long-term VPA treatment on myelination
was striking. Very few, sparse CC1  cells and MAG  and
MBP  fibers were detected in the lateral corpus callosum (Fig.
8, E and K), but not in the medial corpus callosum (Fig. 8, F
and L) and in the anterior commissure (Fig. 8, G and M), thus
suggesting that longer suppression of HDAC activity led to
more severe hypomyelination.
To determine whether the delayed timing of OL differ-
entiation caused by VPA treatment was reversible, we as-
sessed OL differentiation after a recovery period. As expected
from a reversible inhibitor, 2 d after the interruption of VPA
treatment the OL lineage cells were able to resume the age-
appropriate developmental pattern of gene expression charac-
terized by decreased progenitor traits (i.e., Notch1, nestin, and
tenascin), increased levels of the transcriptional activator
Sox10, and of the late differentiation markers MAG and MBP
(Fig. 9 A). The majority of the cells in the corpus callosum of
VPA-treated animals after recovery were immunoreactive for
CC1 (Fig. 9 G) and MAG (Fig. 9 I). However, few myelinated
fibers could be detected in the lateral corpus callosum of
VPA-injected animals (Fig. 9, C and I) compared with the
more extensive myelination observed in PBS-injected controls
(Fig. 9, B and H).
Together, these data support the hypothesis that epige-
netic regulation of gene expression is critical for timely differ-
entiation of OLs in the developing corpus callosum.
After myelination onset, cells in the 
developing corpus callosum acquire more 
permanent changes in chromatin 
components and this renders them 
refractory to the effect of HDAC 
inhibitors
We have previously discussed that the effectiveness of VPA
administration on modulating myelin gene expression in vivo
was limited to a specific temporal window coincident with
the onset of myelination. To understand the molecular
mechanisms defining this developmental window regulated by
HDAC activity, we assessed the presence of AcH3 after each
protocol of VPA injection (Fig. 10 A). Administration of VPA
during the first two postnatal weeks increased the levels of
AcH3 without significantly affecting the acetylation state of
other high molecular weight proteins (Fig. 10 A). In contrast,
administration of VPA during the third postnatal week did not
affect the levels of AcH3 (Fig. 10 A). Because protein acetyla-
tion is the result of the equilibrium between histone acetyl-
transferases (i.e., HATs, such as p300 and CBP) and HDACs
Figure 7. Hypomyelination in VPA-treated rats resulted from delayed differentiation of OL progenitors. Coronal brain sections from PBS- (A and C) and
VPA (B and D) -injected rats (inj1) were processed for immunohistochemistry using antibodies for CC1 (A and D, red) and DAPI as nuclear counterstain.
The number of CC1  cells was referred to as a percentage of the total DAPI   nuclei (E) and was statistically different in the two treatment groups (P   0.01).
The decreased number of CC1  cells was paralleled by an increased number of OL progenitors identified by the surface marker NG2 (F and G,
green). The number of NG2  cells per total DAPI  cells in PBS- and VPA-treated rat corpus callosum showed a statistically significant difference (P  
0.001) (H). (I–M) The increased number of progenitors was not due to impaired exit from the cell cycle. Cells in the S phase of the cell cycle were labeled
in vivo and then identified by immunofluorescence for BrdU (I–L, red) and for NG2 (I and J, green). The number of NG2 /BrdU  cells (M) was not signif-
icantly different between the two groups (P   0.5). (N–Q) The subcortical white matter (scwm) and the corpus callosum (cc) of PBS- (N and P) or VPA (O
and Q) -injected rat brains were double stained with antibodies for MAG (N and O, green) and for PSA-NCAM (O and Q, red). Bar in A, B, I, and J  
100  m. 32  objective, DM RA (Leica). Bar in K–L, 20  m. 63  objective, LSM510 microscope (Carl Zeiss MicroImaging, Inc.).JCB • VOLUME 169 • NUMBER 4 • 2005 584
(Lehrmann et al., 2002; Rouaux et al., 2003), we hypothesized
that the lack of VPA in the third postnatal week was conse-
quent to low levels of HATs. This hypothesis was confirmed
by the detection of decreased protein levels of CBP and p300
during the third postnatal week of development (Fig. 10 B).
The results obtained at p24 suggested that perhaps reversible
acetylation was a mechanism of regulation of gene expression
that was best suited to maintain a certain “plasticity” of gene
expression during early developmental stages. At later devel-
opmental stages, however, it was likely that committed cells
would adopt more stable mechanisms of regulation of gene ex-
pression that would guarantee the maintenance of the differen-
tiated phenotype. Because histone deacetylation is often fol-
lowed by the more stable methylation of lysine 9 in histone H3
(Honda et al., 1975; Eberharter and Becker, 2002; Boulias and
Talianidis, 2004), we asked whether in the corpus callosum the
global changes in gene expression initiated by histone deacety-
lation were also maintained by histone methylation and chro-
matin compaction. To test this possibility, we stained p5 and
p24 brain sections with antibodies specific for methylated his-
tone H3 and for HP1  , a protein that specifically binds to
methylated lysine 9 on histone H3 (MeK9H3) and identifies
the presence of compact chromatin (Bannister et al., 2001;
Lachner et al., 2001). In agreement with our hypothesis, at p5
before the peak of myelination, OL progenitors did not show
MeK9H3  or HP1  immunoreactivity (Fig. 10, C–F). In con-
trast, by p24 the majority of the cells in the corpus callosum
were MeK9H3 /HP-1    (Fig. 10, G–J), thus confirming the
acquisition of compact chromatin structure.
Together, these data indicate that HDAC activity is crit-
ical during the first two weeks of postnatal development of
the corpus callosum and is associated with the reversible
modulation of gene expression at the onset of myelination.
During the third postnatal week, however, after myelination
has ensued, this reversible form of regulation of gene expres-
sion is replaced by more stable changes resulting in chroma-
tin compaction.
Discussion
The process of myelination in the developing corpus callosum
has been well characterized. It is clearly established that ex-
pression of myelin components begins during the first two
postnatal weeks of development (Bjelke and Seiger, 1989;
Bjartmar et al., 1994; Hamano et al., 1996, 1998), but still rela-
tively little is known about the molecular mechanisms underly-
ing this event. We and others have previously reported that my-
elination is a complex phenomenon, requiring the regulated
expression of positive and negative modulators of OL differen-
tiation (Kondo and Raff, 2000a,b; Wang et al., 2001; Marin-
Husstege et al., 2002; Stolt et al., 2002; Liu et al., 2003).
We now show that deacetylation of histone H3 is a criti-
cal mechanism for myelination onset in vivo because it is re-
quired for the down-regulation of differentiation inhibitors and
early progenitor markers. Administration of the HDAC inhibi-
tor VPA during the critical period of myelination onset inhib-
ited the progression of OL progenitors along the lineage. This
arrest in differentiation was characterized by timely exit from
Figure 8. Long-term treatment with HDAC
inhibitors dramatically decreases myelination
in the corpus callosum and anterior commis-
sure of the developing rat. (A) Schematic repre-
sentation of the long-term PBS/VPA treatment
to neonatal rats. Each group was composed
of 12 animals, receiving 13 injections (arrows)
of either PBS (n   6) or VPA (n   6) at the in-
dicated times. Tissue was harvested on p10
(asterisk). Note that in control rats, several OL
were labeled by CC1 (B–D, red) and the ma-
jority of fibers in the lateral corpus callosum
(B and H) and anterior commissure (D) were
myelinated, as indicated by the intense immu-
noreactivity for MAG (B–G, green) and MBP
(H–M, red). In VPA-treated rats, only very few
cells expressed CC1 (E–G, red) and the ma-
jority of the fibers were not myelinated, as
shown by the lack of MAG (E–G, green) and
MBP (K–M, red) immunofluorescence. DAPI
(B–M, blue) was used as nuclear counterstain.
Bar, 20  m. 63  objective, LSM510 micro-
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the cell cycle, persistence of progenitor traits and lack of late
differentiation markers, thereby identifying histone deacetyla-
tion as the molecular link of the transition between cell cycle
exit and differentiation onset.
Deacetylation of histone H3 during myelination onset
was attributed to class I HDACs. The HDAC enzymatic activity
in tissue extracts was selectively inhibited by the inhibitor
TSA but not by the class III inhibitor sirtinol, and only the
class I isoforms (HDAC-1, -2, -3, and -8) showed nuclear lo-
calization. Interestingly, HDAC-1 was predominantly detected
in OL lineage cells throughout development, whereas HDAC-2,
-3, and -8 were also found in neurons and astrocytes. Therefore
class I HDACs were likely to be responsible for the removal of
acetyl groups from histone H3 in OL lineage cells, whereas
class II HDACs played a role in modulating acetylation of
cytosolic substrates
Histone acetylation was previously shown to result from a
balance between the addition (by HATs) and the removal (by
HDACs) of acetyl group on specific lysine residues (Lehrmann
et al., 2002; Rouaux et al., 2003) and to result in a transcription-
ally active chromatin conformation (Eberharter and Becker,
2002), thus implying this secondary modification of histone as a
reversible switch regulating gene expression. In agreement with
this concept, HDAC inhibition in VPA-treated rats created a
disequilibrium characterized by the predominance of HAT ac-
tivity. The resulting increase of H3 acetylation was functionally
associated with high levels of differentiation inhibitors and with
the persistence of progenitor traits. Due to the reversible nature
of this secondary modification of histone H3, we anticipated
that upon interruption of VPA treatment the animals would re-
sume a normal pattern of myelination. Consistent with this hy-
pothesis, after only two days of recovery, progenitors rapidly
down-regulated the inhibitors, up-regulated transcriptional acti-
vators, and expressed OL markers such as CC1 and MAG. In
addition, some of the newly generated OL started to myelinate
the callosal axons, as indicated by the presence of MAG im-
munoreactive fibers. These data support the idea that HDAC
activity is necessary for the repression of genes inhibiting dif-
ferentiation and are in agreement with results recently obtained
in zebrafish (Cunliffe, 2004).
Our study also has important clinical implications because
it suggests that treatment with VPA, a pharmacological agent
currently used in the management of seizures, can negatively
affect myelination in the corpus callosum if delivered during a
critical temporal window of development. The inhibitory effect
of VPA on myelination was observed only if the administration
occurred during the first two postnatal weeks. At later time
points, VPA administration did not affect myelin gene expres-
sion and OL differentiation, thus suggesting the existence of al-
ternative mechanism of regulation of gene expression, occurring
at later developmental stages. It has been reported that histone
deacetylation is often followed by the more stable histone meth-
ylation (Eberharter and Becker, 2002; Boulias and Talianidis,
2004). Indeed, we demonstrated that the reversible deacetyla-
tion of lysine residues on histone H3—observed in cells of the
OL lineage during the first two weeks of development—was
later replaced by the more stable methylation of lysine 9 in his-
tone H3 and by the expression of the HP1   protein, a marker of
chromatin compaction. Therefore, our results identified histone
acetylation as a reversible mechanism regulating the expression
of progenitor traits during early developmental stages, when
progenitors showed a certain degree of “plasticity.” At later de-
velopmental stages, however, the committed cells adopted more
Figure 9. The inhibitory effect of VPA on OL differentiation was reversible.
(A) To address whether OL differentiation was delayed or irreversibly
impaired by VPA treatment, we repeated protocol 1 with a recovery pe-
riod of 3 d after the last injection. At p11 RNA was extracted, and the
myelin gene expression and the presence of inhibitors were assessed by
semi-quantitative RT-PCR. (B and C) Micrographs of coronal brain sections
stained for CC1 (red), MAG (green), and DAPI (blue). Bar, 100  m. 32 
objective, DM RA (Leica). (D–I) Confocal images of the lateral corpus callo-
sum of PBS- or VPA-injected rats after 2 d of recovery. Although extensive
myelination was observed in PBS-treated controls (D, F, and H, white ar-
rows), the majority of cells in the VPA-treated animals were CC1, but only
few of them had started to myelinate (E, G, and I, white arrow). Bar, 20  m.
63  objective, LSM510 microscope (Carl Zeiss MicroImaging, Inc.).JCB • VOLUME 169 • NUMBER 4 • 2005 586
stable mechanisms of repression, dependent on histone methyl-
ation and HP1   binding. These changes defined the acquisition
of compacted chromatin associated with decreased levels of dif-
ferentiation inhibitors possibly to favor the maintenance of the
differentiated phenotype.
The progressive compaction of chromatin during OL de-
velopment was consistent with morphological studies on the
ultrastructure of developing OL in the corpus callosum of neo-
natal rats (Mori and Leblond, 1970; Kozik, 1976; Sturrock,
1976). According to these studies, at p1 progenitors were iden-
tified by the presence of a pale nucleus with dispersed chroma-
tin and abundant cytoplasm (Mori and Leblond, 1970; Stur-
rock, 1976). At p8 the appearance of the differentiating cells,
called “oligodendroblasts,” was characterized by a slightly
higher electron density and by the presence of large conglom-
erates of nuclear chromatin in the inner part of the nuclear
membrane (Kozik, 1976). Finally, around the third week of
postnatal development, the nucleus of OL was characterized by
the presence of very large chromatin aggregates and smaller
granules scattered throughout (Mori and Leblond, 1970; Kozik,
1976; Sturrock, 1976). Our data provide a molecular explana-
tion to this very well-characterized morphological profile be-
cause histone acetylation was consistent with the dispersed
chromatin observed in progenitor cells, histone deacetylation
correlated with the initiation of chromatin compaction observed
around p8, and finally, histone methylation and HP1   binding
were observed coincident with the report of chromatin conden-
sation in mature OL.
In conclusion, this study provides evidence that epige-
netic regulation of gene expression in cells of the OL lineage
modulates timing of OL differentiation in the developing cor-
pus callosum. Although the appearance of nuclear chromatin in
the corpus callosum is a well-established ultrastructural crite-
rion for identification of cells from the OL lineage (Mori and
Leblond, 1970; Kozik, 1976; Sturrock, 1976; Imamoto et al.,
1978), the functional relevance of chromatin compaction in
progenitor differentiation has never been investigated. In this
manuscript we describe the mechanisms responsible for the
progressive compaction of chromatin observed during the mat-
uration of progenitor cells into myelinating OLs. Further, we
identify the biological significance of post-translational modi-
fications of nucleosomal histones as a global event responsible
for timing of OL differentiation and myelination of the devel-
oping corpus callosum.
Materials and methods
Antibodies
HDAC1 (1:6,000 for IHC, 1:4,000 for WB; Affinity BioReagents, Inc.);
HDAC2 (1:100 for IHC, 1:1,000 for WB; Santa Cruz Biotechnology, Inc.);
HDAC3 (1:100 for IHC, 1:500 for WB; Santa Cruz Biotechnology, Inc.);
Figure 10. Global histone deacetylation occurred only during the first two weeks of postnatal development and was followed by histone methylation and
chromatin compaction. (A) To confirm the inhibitory effect of VPA, Western blot analysis was performed on total proteins extracted from the corpus callosum
of injected rats using antibody for AcLys. The increased acetylated 14-kD band was confirmed to be histone H3 by using antibody for AcH3. At p21, VPA
injection did not increase histone H3 acetylation. (B) Western blot analysis of total protein extracted from the body of developing corpus callosum at ante-
rior levels at the indicated time points. The blots were probed with antibodies for the HATs CBP and p300, and actin was used as loading control. (C–J)
Immunofluorescence on cryosections using antibodies specific for methylated lysine 9 on histone H3 (MeK9H3; C, E, G, and I, green) and for HP1  
(C, F, G, and J, red). Co-expression of HP1  and MeK9H3 in p24 corpus callosum reveals the establishment of a compact chromatin structure at later
stages of OL differentiation. Bar, 20  m. 63  objective, LSM510 microscope (Carl Zeiss MicroImaging, Inc.).CHROMATIN CHANGES IN THE DEVELOPING CORPUS CALLOSUM • SHEN ET AL. 587
HDAC4 (1:100 for IHC, 1:1,000 for WB; Upstate Biotechnology);
HDAC5 (1:100 for IHC, 1:500 for WB; Santa Cruz Biotechnology, Inc.);
HDAC6 (1:100 for IHC, 1:500 for WB; Santa Cruz Biotechnology, Inc.);
HDAC7 (1:100 for IHC, 1:500 for WB; Santa Cruz Biotechnology, Inc.);
HDAC8 (1:100 for IHC, 1:500 for WB; Santa Cruz Biotechnology, Inc.);
acetylated-lysine (1:1,000 for IHC and WB; Upstate Biotechnology);
acetylated H3 (1:10,000 for IHC and 1:1,000 for WB; Upstate Biotech-
nology); di-methylated H3 (1:100 for IHC; Upstate Biotechnology); actin
(1:1,000 for WB; Sigma-Aldrich); APC/CC1 (1:50 for IHC; Oncogene
Research Products); Sox10 (1:400 for IHC; a gift from Dr. M. Wagner,
Universität Erlangen-Nürnberg, Germany); NG2 chondroitin sulfate pro-
teoglycan (1:200 for IHC; CHEMICON International); CBP (1:1,000 for
WB; Santa Cruz Biotechnology, Inc.); p300 (1:500 for WB; Santa Cruz
Biotechnology, Inc.); HP1-  (1:500 for IHC; CHEMICON International);
S/L MAG (1:200 for IHC; Zymed Laboratories); MBP (1:1,000; Stern-
berger Monoclonals, Inc.); and BrdU (1:100 for IHC; DakoCytomation).
PBS/VPA injection
The first group of neonatal pups subject to subcutaneous injection (injec-
tion protocol 1) consisted of p6 animals injected either with PBS (n   6) or
with VPA (300 mg/kg weight; n   6). Each animal received a total of
four injections, administered every 12 h for two consecutive days. Injected
rats were then either killed on p8 and the brain tissues were dissected out
and subject to total RNA extraction or protein lysis, or perfused with 4%
PFA for coronal cryosections. The second group of neonatal pups (injec-
tion protocol 2), consisting of p9 animals, was subject to subcutaneous in-
jection of PBS (n   6) or VPA (n   6), repeated every 12 h for 4 times,
and was followed by tissue harvesting at p11. Brain tissue from these in-
jected rats was subject to total RNA extraction or protein lysis. The third
group (injection protocol 3), consisting of p19 pups, received subcutane-
ous injection of PBS (n   6) or VPA (n   6) every 12 h for 4 times fol-
lowed by harvesting on p21. The anterior portion of the corpus callosum
surrounding the bregma was carefully dissected and the extracted proteins
were processed for Western blot analysis. The fourth group (injection pro-
tocol 4), consisting of p3 pups, received a subcutaneous injection of PBS
(n   6) or VPA (n   6) every 12 h for 4 times, followed by tissue harvest-
ing on p5. The long-term treatment consisted of 13 injections from p3 to
p10. The toxicity of the treatment was monitored by daily recording of the
body weight. For the recovery experiments, neonatal rats received the in-
jections as described in protocol 1 and 4 (n   6 for PBS and n   6 for
VPA), followed by a recovery period of three days before sacrifice.
Immunohistochemistry and analysis of corpus callosum and anterior 
commissure
Untreated neonatal rats (p1, p5, p8, p11, and p24) and PBS- or VPA-
injected neonatal rats (see injection protocols) were anesthetized and then
perfused with 4% PFA in 0.1 M phosphate buffer. The whole brains were
removed from the skulls, post-fixed, then cryopreserved in 30% sucrose,
embedded in OCT and sectioned coronally (20  m). Frozen sections were
first permeabilized with blocking buffer (0.1 M phosphate buffer, 5% nor-
mal goat serum [Vector Laboratories], and 0.5% Triton X-100). Note that
for better staining with HDACs it was necessary to process the sections for
antigen retrieval by incubation in citrate buffer (Poly Scientific), pH 6.8, at
65 C for 2 h before the blocking step. Incubation with primary antibodies
against HDACs, myelin proteins, or other lineage progression markers
was performed overnight at RT (see Antibodies section for sources and di-
lutions). The following day, after 1 h incubation with secondary antibodies,
either directly conjugated to specific fluorochromes (whole Ig-Cy3, 1:200;
Sigma-Aldrich) or biotinylated (RPN-1004, 1:200; Amersham Biosci-
ences), the sections were counterstained with DAPI (1:1,000; Molecular
Probes, Inc.) in the absence or presence of avidin-conjugated FITC or
Texas red (RPN-1232 and RPN-1233, diluted 1:500; Amersham Bio-
sciences). Stained sections were visualized using an inverted fluorescence
microscope (DM RA; Leica) and confocal microscopy (LSM510 Meta con-
focal laser scanning microscope; Carl Zeiss MicroImaging, Inc.). The im-
munohistochemical analysis on the rostral corpus callosum at p5 was con-
ducted on coronal sections corresponding to plates 155–160 of the p0
images of the “Atlas of the Developing Rat Nervous System” (Paxinos et
al., 1994), upon adjustments of the distance from bregma to lambda at
p0 to the measured distance between these two sutures at p5. The anterior
commissure was analyzed in sections corresponding to plates 156 and
157 of the same atlas (Paxinos et al., 1994). The immunohistochemical
analysis of the anterior portion of the body of the corpus callosum at p24
was conducted posterior to the genu, on coronal sections corresponding
to plates 15–19 of the atlas “The Rat Brain in Stereotaxic Coordinates”
(Paxinos and Watson, 1986). The anterior commissure was analyzed in
coronal brain sections corresponding to plates 18 and 19 of the same atlas
(Paxinos and Watson, 1986). The “medial corpus callosum” was defined
as the region corresponding to  1 L,  1R of the same atlases. For the
functional studies on PBS- or VPA-injected rats of different neonatal ages,
the rostral corpus callosum and the anterior commissure were analyzed us-
ing similar criteria, adjusting the Atlas to the exact bregma to lambda dis-
tance at each developmental age (Paxinos and Watson, 1986; Paxinos et
al., 1994).
Western blot analysis
Upon carefully removing the skin over the skull, the positions of the bregma
and lambda sutures were marked on the brain surface. These positions
were used as a reference point in dissecting out the same regions of corpus
callosum from rats of different developing stages. A coronal slice around
the bregma was dissected out, and the corpus callosum was excised under
a dissection microscope (Nikon) and used for either protein or RNA extrac-
tion. Tissue lysates from freshly dissected corpus callosum were prepared
by digestion in a buffer containing 50 mM Hepes, pH 7.0, 250 mM NaCl,
0.15% Nonidet P-40, 1 mM DTT, 1 mM EDTA, 0.01% PMSF, 1 mM apro-
tinin, and 1 mM leupeptin for 15 min on ice. This was followed by me-
chanical disruption via serial passages through a series of syringes
equipped with different-sized needles (18G11/2, 22G11/2, and 26G3/8).
Cell membranes were further disrupted by sonication on ice at the highest
output (twice, 30 s each; cells were kept on ice for 1 min between each
pulse). After high speed centrifuge, protein concentration was determined
using the Bradford’s method (Bio-Rad Laboratories protein assay) and
equal amounts (100  g) were loaded on SDS-PAGE for separation. Trans-
fer of protein onto a 0.22- m nitrocellulose membrane was conducted us-
ing a Bio-Rad Laboratories apparatus at 30 V for 16–18 h in a transfer
buffer containing 25 mM Tris base, 192 mM glycine, 20% (vol/vol) meth-
anol, and 0.04% SDS, pH 8.3. Western blot analysis was performed as
reported previously (Casaccia-Bonnefil et al., 1997, 1999) using the ap-
propriate dilutions of primary and secondary antibodies (see Antibodies
section for details). The immunoreactive bands were detected by ECL Plus
Western Blotting Detection System (Amersham Biosciences). Equal protein
loading was guaranteed by probing the blots with antibody against actin.
RT-PCR
Total RNA was isolated using RNeasy Mini kit (QIAGEN) from individu-
ally dissected rat corpus callosum. Total RNA (9  g/each sample) was
used in 40  l of reverse transcription reaction. The PCR was performed in
a 20- l reaction mixture containing 2  l cDNA as template and 0.1  M
specific oligonucleotide primer pair. Cycle parameters were 30 s at 94 C,
30 s at 50 C, and 1.5 min at 72 C for 25 cycles. The following oligonu-
cleotide primers were used: for rat cerebroside-galactosyl transferase
(CGT) the forward primer was 5 -GGAGTGCTGTTGGAATAGCAA-3 ,
and the reverse primer was 5 -CGTACTCCTAGAACACAGACTT-3 ; for
rat MAG, the forward primer was 5 -CACCTCGAGTCGCCTTTGCCATC-
CTGATT-3 , and the reverse primer was 5 -TCTCCATGGCCTTGACTCG-
GATTTCTGCATAC-3 ; for rat MBP, the forward primer was 5 -ATGGCAT-
CACAGAAGAGACC-3 , and the reverse primer was 5 -CATGGGAG-
ATCCAGAGCGGC-3 ; for rat Sox10, the forward primer was 5 -GGAG-
CAAGACCTATCAGAGGT-3 , and the reverse primer was 5 -CAA-
AGGTCTCCATGTTGGACA-3 ; for rat Notch-1, the forward primer was
5 -CAACGGCACTGAAGCCTGTGT-3 , and the reverse primer was 5 -
GCACAGTCATCAATGTTGTCA-3 ; for rat nestin, the forward primer was
5 -TGCAGCCACTGAGGTATCTG-3 , and the reverse primer was 5 -
CAGTTCCCACTCCTGTGGTT-3 ; for rat tenascin, the forward primer was
5 -AACAGGTCTCAGAGAGGCCA-3 , and the reverse primer was 5 -
CTTCTCTGCGGTCTCCAAAC-3 ; for rat Jagged-1, the forward primer
was 5 -AACAGAACACAGGGATTGCC-3 , and the reverse primer was
5 -CTTGCCCTCGTAGTCCTCAG-3 ; for rat actin, the forward primer was
5 -TGGAATCCTGTGGCATCC-3 , and the reverse primer was 5 -TCG-
TACTCCTGCTTGCTG-3 .
Total HDAC enzymatic activity measurement
HDAC activity was measured by using HDAC Activity Assay/Drug Discov-
ery Kit (BIOMOL Research Laboratories, Inc.). Experimental procedures
were designed and performed according to the protocol provided within
the kit. In brief, tissue lysates from the rat corpus callosum (prepared accord-
ing to the same procedure described in Western blot analysis section) were
used as sources for HDAC activity. Sample lysates containing 100  g pro-
tein were added to a 96-well plate in 25  l HDAC assay buffer (BIOMOL
Research Laboratories, Inc.). A fluorimetric acetylated substrate was added
and the reaction was allowed occurring at RT for 1 h, then incubated with
developer for 10–15 min. Enzymatic activity was evaluated in a microtiterJCB • VOLUME 169 • NUMBER 4 • 2005 588
plate–reading fluorimeter (excitation   360 nm, detection of emitted light  
460 nm). HeLa nuclear extract (KI-140) was used as positive control.
BrdU incorporation in vivo and TUNEL
Neonatal rat pups received 10 mg/Kg BrdU injection 1 h before sacrifice.
After perfusion and cryopreservation, brains were sectioned and stained
with cellular markers. For immunolabeling with anti-BrdU antibodies, after
the completion of the first staining, the cells were then treated with 2N HCl
for 10 min at 37 C in order to denature DNA, followed by equilibration in
0.1 M sodium borate, pH 8.6, for 10 min. The primary antibody for anti-
BrdU (DakoCytomation) was used at 1:100 dilution in PGBA containing
0.5% Triton X-100 for at least 3 h at RT, followed by Cy3-conjugated
whole-Ig secondary antiserum. Cells were then counterstained with DAPI
for nuclei visualization. The identification of apoptotic cells was performed
using the ApopTag plus kit from CHEMICON International on cryosec-
tions, following the manufacturer’s instructions.
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